Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer is challenging. The Oncotype DX gene assay is often used. Using a database of 221 patients a simple 2-rule model was developed and validated on an independent group of 319 patients. The model categorizes patients unlikely to benefit from the test thus achieving significant avoidance of cost. Background Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX’s usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination. Patients and Methods Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution’s set of 319 patients. Results The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER < 20%) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0% and 2%, and for LG+PR patients who had an RS ≥ 26 were 0% and 2.6%. In the validation set, 28% (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG + PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX. Conclusion A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.
Thoracic intervertebral disk herniation is a rare phenomenon. It is a particularly uncommon entity in the pediatric population. As such, the diagnosis and management of thoracic disk herniation can be a considerable challenge. As illustrated in our case report, the clinician's focus should not exclusively rest on lumbar disk pathology as the etiology for such rapidly evolving neuromuscular deficits. Thoracic disk herniation must be included in the differential diagnosis, and appropriate diagnostic workup should be instituted in an expeditious manner. Plain radiographic studies may not delineate the causative factor of pathology, and emergent magnetic resonance imaging can aid in obtaining a timely diagnosis. Early intervention and decompression have been shown to significantly improve functional recovery.
A hibernoma is an uncommon, benign tumor composed of brown adipose tissue. It is a rare but documented cause of neck masses. Hibernomas may be first diagnosed not by clinical examination, but incidentally through radiologic tests assessing the metabolic activity of certain tissues. These tumors are by definition benign entities but, given their propensity for growth over time, they require complete extirpation to prevent recurrence. Different radiologic modalities have been used to evaluate hibernomas, including computed tomography scan, magnetic resonance imaging, fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography, and angiography. It is rare for a hibernoma to be discovered through Tc-99m lymphoscintigraphy.
The 3 leading causes of aortic stenosis (AS) in adults are calcific degeneration of a normal trileaflet aortic valve (AV), calcific degeneration of a congenital bicuspid AV, and rheumatic AS. Therapeutic options in patients with severe AS include aortic valve replacement (AVR), transcatheter aortic valve implantation (TAVI), or aortic valve bypass (AVB). An AVB involves the placement of a valved conduit between the apex of the left ventricle and the descending thoracic aorta. AVB serves as a useful alternative to treat severe AS in patients deemed high risk for conventional AVR (ie, porcelain aorta, previous cardiac surgery) or TAVI (ie, severe aorto-iliac disease, limited experience, lack of hybrid operating room). Advantages of on-pump AVB include the avoidance of aortic cannulation, cross-clamping, and cardioplegic cardiac arrest. The procedure can also be performed without cardiopulmonary bypass. In this article, the authors review the circulatory physiology, perioperative anesthetic management, the role of intraoperative transesophageal echocardiography, and surgical considerations of AVB surgery through 3 cases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.